# Affimed N.V. (AFMD)

Source: https://www.quantisnow.com/company/AFMD
Generated: 2026-11-09T21:03:35.288Z

- Ticker: AFMD
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: affimed.com

## About

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

## Latest AFMD news and filings

- 2025-05-20 20:01 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-affimed-nv-6050034)
- 2025-05-14 12:54 UTC [Analyst Downgrade] [Affimed Therapeutics downgraded by H.C. Wainwright](https://www.quantisnow.com/insight/affimed-therapeutics-downgraded-by-hc-wainwright-6037832)
- 2025-05-14 11:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-6037535)
- 2025-05-14 10:45 UTC [Affimed Announces Receipt of Nasdaq Delisting Notice](https://www.quantisnow.com/insight/affimed-announces-receipt-of-nasdaq-delisting-notice-6037420)
- 2025-05-13 12:52 UTC [Analyst Downgrade] [Affimed Therapeutics downgraded by Leerink Partners](https://www.quantisnow.com/insight/affimed-therapeutics-downgraded-by-leerink-partners-6034953)
- 2025-05-13 12:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-6034844)
- 2025-05-13 12:15 UTC [Affimed Announces Filing for the Opening of Insolvency Proceedings](https://www.quantisnow.com/insight/affimed-announces-filing-for-the-opening-of-insolvency-proceedings-6034822)
- 2025-05-01 20:05 UTC [SEC Form NT 20-F filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-nt-20-f-filed-by-affimed-nv-6013279)
- 2025-04-29 14:00 UTC [Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting](https://www.quantisnow.com/insight/affimed-shows-higher-exposure-of-afm24-is-associated-with-significantly-6006521)
- 2025-04-23 14:05 UTC [Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting](https://www.quantisnow.com/insight/affimed-announces-acceptance-of-three-abstracts-for-presentation-at-the-5997724)
- 2025-04-21 12:32 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5994222)
- 2025-04-21 10:30 UTC [Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement](https://www.quantisnow.com/insight/affimed-announces-receipt-of-nasdaq-deficiency-notice-regarding-minimum-bid-5993977)
- 2025-03-25 20:30 UTC [Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting](https://www.quantisnow.com/insight/affimed-announces-acceptance-of-afm24-abstract-on-dose-optimization-for-5959560)
- 2025-03-03 11:30 UTC [Conference Announcement] [Affimed to Present at the Leerink Partners Global Healthcare Conference 2025](https://www.quantisnow.com/insight/affimed-to-present-at-the-leerink-partners-global-healthcare-conference-5918836)
- 2025-02-14 13:18 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-affimed-nv-5889133)
- 2024-12-17 11:36 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5815830)
- 2024-12-17 11:30 UTC [Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)](https://www.quantisnow.com/insight/affimed-reports-positive-clinical-update-on-afm24atezolizumab-combination-therapy-in-5815819)
- 2024-12-09 18:30 UTC [Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)](https://www.quantisnow.com/insight/affimed-reports-promising-phase-1-efficacy-and-safety-data-for-5805253)
- 2024-12-09 11:30 UTC [Earnings Date] [Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer](https://www.quantisnow.com/insight/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-5804539)
- 2024-12-08 17:00 UTC [Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients](https://www.quantisnow.com/insight/affimed-announces-positive-results-demonstrating-safety-and-efficacy-of-acimtamig-5804411)
- 2024-11-14 12:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5773138)
- 2024-11-14 11:30 UTC [Earnings Date] [Affimed Reports Third Quarter 2024 Financial Results & Business Update](https://www.quantisnow.com/insight/affimed-reports-third-quarter-2024-financial-results-business-update-5772981)
- 2024-11-12 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-affimed-nv-5764988)
- 2024-11-08 22:09 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-affimed-nv-5763237)
- 2024-11-06 11:30 UTC [Earnings Date] [Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024](https://www.quantisnow.com/insight/affimed-to-report-third-quarter-2024-financial-results-corporate-update-5754428)
- 2024-11-05 14:00 UTC [Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma](https://www.quantisnow.com/insight/affimed-announces-acceptance-of-three-abstracts-at-the-2024-ash-5752564)
- 2024-11-04 18:08 UTC [SEC Form F-3 filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-f-3-filed-by-affimed-nv-5750198)
- 2024-10-24 18:49 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-affimed-nv-5736934)
- 2024-10-15 10:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5724524)
- 2024-09-11 11:41 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5689942)
- 2024-09-10 10:30 UTC [Conference Announcement] [Affimed to Present at the Cantor Global Healthcare Conference 2024](https://www.quantisnow.com/insight/affimed-to-present-at-the-cantor-global-healthcare-conference-2024-5688115)
- 2024-09-05 10:36 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5683187)
- 2024-09-05 10:30 UTC [Earnings Date] [Affimed Reports Second Quarter 2024 Financial Results & Business Update](https://www.quantisnow.com/insight/affimed-reports-second-quarter-2024-financial-results-business-update-5683165)
- 2024-09-03 12:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5679110)
- 2024-09-03 11:45 UTC [Leadership Update] [Affimed Appoints Shawn M. Leland as Chief Executive Officer](https://www.quantisnow.com/insight/affimed-appoints-shawn-m-leland-as-chief-executive-officer-5678977)
- 2024-08-29 10:30 UTC [Earnings Date] [Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024](https://www.quantisnow.com/insight/affimed-to-report-second-quarter-2024-financial-results-corporate-update-5675679)
- 2024-06-26 20:52 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5579245)
- 2024-06-13 14:23 UTC [Market Chatter] [Laidlaw & Co. Maintains Buy on Affimed, Raises Price Target to $25](https://www.quantisnow.com/insight/laidlaw-co-maintains-buy-on-affimed-raises-price-target-to-5555687)
- 2024-06-13 10:18 UTC [Market Chatter] [HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target](https://www.quantisnow.com/insight/hc-wainwright-co-reiterates-buy-on-affimed-maintains-10-price-5554885)
- 2024-06-12 11:56 UTC [SEC Form 6-K] [SEC Form 6-K filed by Affimed N.V.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-affimed-nv-5552673)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AFMD
- Earnings history: https://www.quantisnow.com/earnings/AFMD
- Dividend history: https://www.quantisnow.com/dividends/AFMD
- Insider transactions: https://www.quantisnow.com/insiders/AFMD
- Options chain: https://www.quantisnow.com/options/AFMD
- SEC 8-K filings only: https://www.quantisnow.com/company/AFMD/8-k
- RSS and alerts for AFMD: https://www.quantisnow.com/docs/rss-feeds.md